2Borner MM, Dietrich D, Stupp R, et al. Phase Ⅱ study of capecitabine and oxaliplatln in first-and secong-line treatment of advanced or metastatic colorectal cancer[ J ]. Clin Onco1,2002,20(7) :1759-1766.
3Levi F, Zidanik, Misser TL, et al. For the international organization for cancer chemothempy:Randomised multicentre of chemotherapy with oxaliplatin, fliorouracil, and folinate acid in metastatic colorectal cancer[ J]. Cancer,1997,350( ) :681-686.
2Sakamoto J, Clin K, Kondo K, et al. Phase lI study of a 4 - week capecitabine regimen in advanced or recurrent gastric- cancer[ J ]. Anticaneer Drugs,2006,17 (2) :231 - 236.
3Sawada N, Kondoh K, Moil K. Enhancement of eapeeitabine efficacy by oxaliplatin in human eolorectal and gastric canc- er xenografts [ J ]. Oncology Reports, 2007,18 ( 4 ) : 775 - 778.
4Dlaz - Rubio E, Tabernero J, G6mez - Espafia A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous - infusion fluorouracil plus oxaliplatin as first -line therapy in metastatic colorectal cancer: final re- port of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial [ J ]. J Clin Oncol, 2007,25 (27) : 4224 - 4230.
5Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin(XELOX) versus 5 - fluorouracil/leucovorin plus oxaliplatin( FOLFOX- 6)as first- line treatment for meta- static colorectal cancer[ J ]. Int J Cancer,2011,128 (3) : 682 - 690.
6Willett CG, Boucher Y, Ditomaso E, et al. Direct evidence that the VEGF -specific antibody bevacizumab has antivas- cular effects in human rectal cancer[ J ]. Nat Med,2004,10 (2) :145 - 147.
7Tyagi P, Grothey A. Commentary on a phase III trim of bev- acizumab plus XELOX or FOLFOX4 for first - line treat- ment of metastatic colorectal cancer: the N016966 trial[ J ]. Clin Colorectal Cancer,2006,6(4) :261 -264.
8Doi T, Boku N,Kato K,et al. Phase I/II study of capecit- abine plus oxaliplatin (XELOX)plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer[J]. Jpn J Clin 0ncol,2010,40(10) :913 -920.
9Uchima Y, Nishii T, Iseki Y, et al. Retrospective analysis of capecitabine and oxaliplatin ( XELOX ) plus bevacizumab as a first- line treatment for Japanese patients with metastatic colorectal cancer [ J ]. Mol Clin Oncol, 2014,2 ( 1 ) : 134 - 138.
10Berreta M, Aprite G, Nasti G, et al. Oxaliplatin and capecitabine (XELOX)based chemotherapy in the treat- ment of metastatic colorectal cancer: the right choice in elderly patients[ J]. Anticancer Aqents Med Chem,2013, 13(9) :1344 - 1353.
